- Company
- Mavyret’s 8-week indication approved in Korea
- by Eo, Yun-Ho Nov 11, 2019 10:40pm
- A hepatitis C treatment Mavyret is to soon be available as an eight-week treatment in Korea, after its approval in the U.S. After receiving an approval from the U.S. Food and Drug Administration (FDA) first, AbbVie received an approval from Korean Ministry of Food and Drug Safety (MFDS) last month for another indication as an eight-wee
- Opinion
- [Reporter's view] DC the absolute power behind hospital
- by Eo, Yun-Ho Nov 11, 2019 11:08am
- When each hospital’s Drug Committee (DC) is convened, pharmaceutical companies starts a fierce war to land a favorable drug deal. Just like any war in the world, the ‘DC war’ has a winner and a loser. Unfortunately, not always do the winners deserve a win or the losers deserve their defeat. To land a ‘drug code-in’ deal at som
- Policy
- World's most expensive drug Zolgensma to challenge Spiranza
- by Lee, Hye-Kyung Nov 11, 2019 06:11am
- Launching of the most expensive drug in the world, Zolgensma (onasemnogene abeparvovec-xioi), with a price tag of 2.5 billion won per dosage, has gotten Korean health authority and pharmaceutical industry anxious. Although the drug had an allegation of data manipulation from animal testing two months after the U.S. Food and Drug Administrati
- Policy
- On a mission to eradicate KOEDC’s deep-rooted ill practice
- by Lee, Jeong-Hwan Nov 10, 2019 10:00pm
- Sources confirmed Korea Orphan and Essential Drug Center (KOEDC) submitted the National Assembly (NA) a plan to resolve its issue of redirecting profit made from drug expense gap, as it was pointed out at the latest NA Annual Audit. The center is committed to eradicate its deep-rooted practice of making profit from drug price difference
- Policy
- Eliquis faces 42 generics after patent invalidated
- by Lee, Tak-Sun Nov 10, 2019 10:00pm
- The list of generics launched in the New Oral Anticoagulant (NOAC) Eliquis (apixaban) market is getting longer by the day. Especially after generic manufacturing companies won the case invalidating Eliquis’ patent in last March, number of regulator-approved generics has skyrocketed. Ministry of Food and Drug Safety (MFDS) confirmed that
- Policy
- “Less on chronic drug, but more on innovative drug”
- by Lee, Jeong-Hwan Nov 10, 2019 09:59pm
- Claims have been made that the government drug expenditure model should be fundamentally reformed, instead of adopting new drug-centered drug pricing policy, to simultaneously better Korean patient's access to new and breakthrough treatments, and to secure financial health of National Health Insurance (NHI). The criticism is that the go
- Product
- Vibramycin restocking delayed again, but for how long?
- by Kim, Min-Gun Nov 10, 2019 09:58pm
- Restocking of Pifzer Korea’s antibiotic Vibramycin-N (doxycycline) 100mg (500T), initially scheduled in November, has been delayed again. Since July last year, this is an eighth supply delay notice. Number of pharmacies is to experience inconvenience due to the delay. On November 5, Pfizer Korea notified all drug distribution companie
- InterView
- "Use of RWD and AI in new drug development will increase”
- by Park, sangjun Nov 8, 2019 08:55am
- Global pharmaceutical companies have been increasingly attempting to implement artificial intelligence (AI) and real world data (RWD) to the process of developing new drugs believing that using AI can drastically reduce the development period and maximize treatment efficacy. Global leaders in the pharmaceutical industry such as Pfizer, GlaxoS
- Company
- Generic to pay for original’s lowered pricing loss?
- by Kim, Jin-Gu Nov 8, 2019 08:55am
- To this date, a boundary of patent infringement damage against generic was up to ‘sales profit of generic’. But now a lawsuit claims the damages should include ‘loss made from original’s price reduction’ due to generics’ launch. Related court case is currently waiting for the Supreme Court’s final decision. Lilly Korea and two Kor
- Opinion
- [Eyes of a Reporter] Are you a ‘good company?’
- by An, Kyung-Jin Nov 8, 2019 08:45am
- Every year around this time, one book hikes up the best seller ranking at book stores. The book, ‘Trend Korea Series’ by Professor Kim Nando of Seoul National University, summarizes next year’s trend in Korea with a list of keywords. ‘Trend Korea 2020’ had a top ten consumer trend keyword list including ‘fair play’. The book explains
